Traws Pharma Inc TRAW
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-07-25 |
| Shares Out. | 15,230,000 |
| Website | trawspharma.com/ ↗ |
| Phone | 12677593680 |
| Employees | 7 |
| Net Income | -$7.1M |
| Free Cash Flow | -$17.9M |
| Total Assets | $8.2M |
| Total Liabilities | $13.5M |
| Equity | -$5.3M |
About Traws Pharma Inc
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Traws Pharma Inc is a publicly traded company under the ticker symbol TRAW on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)